
124.83 Delayed Data As of 4:00pm ET | ![]() Today’s Change | 46.84 Today|||52-Week Range 220.20 | -18.47% Year-to-Date |
The 18 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 162.50, with a high estimate of 210.00 and a low estimate of 45.00. The median estimate represents a +30.18% increase from the last price of 124.83.
The current consensus among 21 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.